Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,645.50GBp
21 Feb 2017
Change (% chg)

9.00 (+0.55%)
Prev Close
1,636.50
Open
1,636.50
Day's High
1,649.50
Day's Low
1,635.00
Volume
8,551,734
Avg. Vol
9,482,377
52-wk High
1,745.56
52-wk Low
1,355.00

Select another date:

Tue, Feb 14 2017

Photo

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

BRIEF-GSK announces positive final stage results for two-drug HIV treatment

* Announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

GSK asks judge to toss several claims from generic Paxil case

GlaxoSmithKline has urged a federal judge in Illinois to toss several claims to a lawsuit alleging that a generic version of its antidepressant Paxil caused a Reed Smith partner's suicide.

GlaxoSmithKline and Gilead to face off at HIV meeting next week

LONDON GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.

GlaxoSmithKline and Gilead to face off at HIV meeting next week

LONDON, Feb 8 GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.

BRIEF-GSK says launched flonase sensimist allergy relief nationwide

* GSK Consumer Healthcare - announced nationwide launch of flonase sensimist allergy relief Source text for Eikon: Further company coverage:

Weak pound buoys GSK but drugmaker warns on 2017 generic threat

LONDON, Feb 8 GlaxoSmithKline sales and profits jumped in the fourth quarter, helped by falling sterling, but the drugmaker cautioned profit growth could be impacted in 2017 by generic competition to its top-selling lung drug Advair.

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

LONDON Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

LONDON, Feb 6 Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Select another date:

More From Around the Web